| First Author | Nebbioso A | Year | 2018 |
| Journal | PLoS Genet | Volume | 14 |
| Issue | 6 | Pages | e1007362 |
| PubMed ID | 29879107 | Mgi Jnum | J:262673 |
| Mgi Id | MGI:6161480 | Doi | 10.1371/journal.pgen.1007362 |
| Citation | Nebbioso A, et al. (2018) Cancer epigenetics: Moving forward. PLoS Genet 14(6):e1007362 |
| abstractText | Defects in chromatin modifiers and remodelers have been described both for hematological and solid malignancies, corroborating and strengthening the role of epigenetic aberrations in the etiology of cancer. Furthermore, epigenetic marks-DNA methylation, histone modifications, chromatin remodeling, and microRNA-can be considered potential markers of cancer development and progression. Here, we review whether altered epigenetic landscapes are merely a consequence of chromatin modifier/remodeler aberrations or a hallmark of cancer etiology. We critically evaluate current knowledge on causal epigenetic aberrations and examine to what extent the prioritization of (epi)genetic deregulations can be assessed in cancer as some type of genetic lesion characterizing solid cancer progression. We also discuss the multiple challenges in developing compounds targeting epigenetic enzymes (named epidrugs) for epigenetic-based therapies. The implementation of acquired knowledge of epigenetic biomarkers for patient stratification, together with the development of next-generation epidrugs and predictive models, will take our understanding and use of cancer epigenetics in diagnosis, prognosis, and treatment of cancer patients to a new level. |
